{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:42:06Z","timestamp":1790080926335,"version":"4.0.1"},"reference-count":23,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":118,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharmacology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1002\/jcph.495","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T10:58:55Z","timestamp":1426071535000},"page":"909-919","source":"Crossref","is-referenced-by-count":44,"title":["Clinical drug interaction profile of idelalisib in healthy subjects"],"prefix":"10.1002","volume":"55","author":[{"given":"Feng","family":"Jin","sequence":"first","affiliation":[{"name":"Gilead Sciences, Inc.; Foster City CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Robeson","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.; Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafeng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.; Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candra","family":"Moyer","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.; Foster City CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Wilbert","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.; Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Murray","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.; Foster City CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srini","family":"Ramanathan","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.; Foster City CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,5,6]]},"reference":[{"issue":"4","key":"10.1002\/jcph.495-BIB0001|jcph495-cit-0001","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri1056","article-title":"PI3K in lymphocyte development, differentiation and activation","volume":"3","author":"Okkenhaug","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1002\/jcph.495-BIB0002|jcph495-cit-0002","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tibs.2005.02.008","article-title":"Signalling by PI3K isoforms: insights from gene-targeted mice","volume":"30","author":"Vanhaesebroeck","year":"2005","journal-title":"Trends Biochem Sci"},{"issue":"16","key":"10.1002\/jcph.495-BIB0003|jcph495-cit-0003","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1182\/blood-2010-11-315705","article-title":"The role of phosphatidylinositol 3-kinase-\u03b4 in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1002\/jcph.495-BIB0004|jcph495-cit-0004","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood.V98.10.3050","article-title":"Survival of leukemic B cells promoted by engagement of the antigen receptor","volume":"98","author":"Bernal","year":"2001","journal-title":"Blood"},{"issue":"2","key":"10.1002\/jcph.495-BIB0005|jcph495-cit-0005","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"issue":"13","key":"10.1002\/jcph.495-BIB0006|jcph495-cit-0006","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1002\/jcph.495-BIB0007|jcph495-cit-0007","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1002\/jcph.495-BIB0008|jcph495-cit-0008","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1002\/jcph.495-BIB0009|jcph495-cit-0009","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1182\/blood.V122.21.5570.5570","article-title":"Pharmacokinetics, metabolism and excretion of idelalisib [ASH abstract]","volume":"122","author":"Jin","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1002\/jcph.495-BIB0010|jcph495-cit-0010","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1177\/0091270006292625","article-title":"Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities","volume":"46","author":"Kirby","year":"2006","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1002\/jcph.495-BIB0011|jcph495-cit-0011","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00007691-200406000-00018","article-title":"Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes","volume":"26","author":"Penzak","year":"2004","journal-title":"Ther Drug Monit"},{"issue":"12","key":"10.1002\/jcph.495-BIB0012|jcph495-cit-0012","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1124\/dmd.106.011742","article-title":"Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam","volume":"34","author":"Chen","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1002\/jcph.495-BIB0013|jcph495-cit-0013","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/FJC.0b013e31817b5b5a","article-title":"Effects of atazanavir\/ritonavir or fosamprenavir\/ritonavir on the pharmacokinetics of rosuvastatin","volume":"51","author":"Busti","year":"2008","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"10.1002\/jcph.495-BIB0014|jcph495-cit-0014","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/BF00615223","article-title":"Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects","volume":"34","author":"Perucca","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"issue":"21","key":"10.1002\/jcph.495-BIB0015|jcph495-cit-0015","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood.V116.21.1774.1774","article-title":"Clinical pharmacokinetics of CAL-101, a p110\u03b4 isoform-selective PI3K inhibitor, following single- and multiple-dose administration in healthy volunteers and patients with hematological malignancies [ASH abstract]","volume":"116","author":"Webb","year":"2010","journal-title":"Blood."},{"key":"10.1002\/jcph.495-BIB0016|jcph495-cit-0016","unstructured":"http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm292362.pdf"},{"issue":"2","key":"10.1002\/jcph.495-BIB0017|jcph495-cit-0017","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.clpt.2004.03.010","article-title":"Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine","volume":"76","author":"Simonson","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1002\/jcph.495-BIB0018|jcph495-cit-0018","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jcph.200","article-title":"Suitability of digoxin as a P-glycoprotein probe: implications of other transporters on sensitivity and specificity","volume":"54","author":"Nader","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1002\/jcph.495-BIB0019|jcph495-cit-0019","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0163-7258(96)00140-4","article-title":"Human P450 metabolism of warfarin [abstract]","volume":"73","author":"Kaminsky","year":"1997","journal-title":"Pharmacol Ther."},{"issue":"1","key":"10.1002\/jcph.495-BIB0020|jcph495-cit-0020","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0022-3565(25)24810-8","article-title":"Selective inhibition of warfarin metabolism by diltiazem in humans","volume":"257","author":"Abernethy","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1002\/jcph.495-BIB0021|jcph495-cit-0021","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","article-title":"Identification and biological activity of the active metabolite of clopidogrel","volume":"84","author":"Savi","year":"2000","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1002\/jcph.495-BIB0022|jcph495-cit-0022","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1002\/jcph.495-BIB0023|jcph495-cit-0023","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1124\/dmd.107.016089","article-title":"Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions","volume":"35","author":"Dixit","year":"2007","journal-title":"Drug Metab Dispos"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.495","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/jcph.495\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T21:21:30Z","timestamp":1747776090000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcph.495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,6]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"URL":"https:\/\/doi.org\/10.1002\/jcph.495","relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5,6]]}}}